Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSun Yat-sen University
About this trial
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).
Eligibility criteria
Qualifiers
Voluntarily sign a written informed consent form (ICF).
Age at the time of enrollment is >= 18 and under 80 years old, with no gender restrictions.
The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
Expected survival period >= 3 months.
Disqualifiers
lymph node metastasis;
The tumor surrounds the renal artery;
Renal vein cancer thrombus;
Diffuse tumor growth, with no clear boundary from normal renal parenchyma;
Trial design
Treatments tested in this trial
- QL1706 Combined With Lenvatinib
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov